Lupus Trials News

The best and brightest are working toward finding better treatments and ultimately a cure for lupus. Read about how the most important influencers in the lupus community are effecting lupus research, along with other issues that matter most to you.

Lupus Therapeutics Partners with AbbVie on Clinical Trial Recruitment Efforts in SLE Through LuCIN Lupus Clinical Trial Network

NEW YORK, N.Y., Oct. 24, 2023 – Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, announces a...

Study Reported Telitacicept Showed Favorable Effectiveness and Safety for SLE

Dec. 1, 2023 A new paper published in Lupus Science & Medicine on the results of a study in China...

Read More

Summary Highlights of Important Research Presented at ACR Convergence 2023

November, 2023 At the recent ACR Convergence 2023, the annual meeting of the American College of Rheumatology, important lupus clinical...

Read More

LRA Highlights Groundbreaking Lupus Research at ACR Convergence 2023

This information is brought to you by the Lupus Research Alliance and Lupus Therapeutics and is not sponsored by, nor a part of,...

Read More

Positive One-Year Results of PALS Program Published in Prestigious Rheumatology Journal

NEW YORK, NY. Oct. 26, 2023. Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, is proud to...

Read More

Lupus Therapeutics Partners with AbbVie on Clinical Trial Recruitment Efforts in SLE Through LuCIN Lupus Clinical Trial Network 

NEW YORK, N.Y., Oct. 24, 2023 – Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, announces a...

Read More

Lupus Therapeutics Announces Partnership to Support the Evaluation of Natural Killer (NK) Cell Therapy in Lupus Nephritis

NEW YORK, N.Y. — October 17, 2023: Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, today announced a...

Lupus Therapeutics Announces Partnership to Support the Evaluation of Natural Killer (NK) Cell Therapy in Lupus Nephritis

NEW YORK, N.Y. — October 17, 2023: Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, today announced...

Read More

Lupus Therapeutics PALS Program Expansion

October 1, 2023 Call for Individuals to Serve as a Trained Peer Educator Lupus Therapeutics, the clinical affiliate of Lupus...

Read More

Data Shows Voclosporin Preserves Kidney Function for Three Years

July 19,2023 The LRA is pleased to share news announced by Aurinia Pharmaceuticals of published results showing that the lupus...

Read More

Project CHANGE Launches Pilot Programs in Atlanta, Nashville, and Philadelphia to Increase Diversity in Lupus Clinical Research

New York, NY. June 29, 2023. Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, today announced the...

Read More

Analysis Found Rituximab Biosimilar Showed Effectiveness in Treating Pediatric Lupus Nephritis

Rituximab biosimilar BCD020 showed effectiveness in treating lupus nephritis in a pediatric population according to results of a retrospective study...

Read More

Lupus Therapeutics Partners to Evaluate Potential Treatment for SLE and Lupus Nephritis Through North American Trial Network

NEW YORK, N.Y. — June 2, 2023 Lupus Therapeutics announced the start of a collaboration to conduct three Phase 3...

Lupus Therapeutics Partners to Evaluate Potential Treatment for SLE and Lupus Nephritis Through North American Trial Network

NEW YORK, N.Y. — June 2, 2023 Lupus Therapeutics announced the start of a collaboration to conduct three Phase 3...

Read More

EULAR Presentation Showed Upadacitinib Improved Lupus Disease Activity

May 31, 2023 We are pleased to share encouraging news from EULAR, the annual meeting of the European Alliance of...

Read More

Lupus Research Alliance and its Clinical Research Affiliate Lupus Therapeutics Launch the Lupus Landmark Study to Accelerate Personalized Treatments in Lupus

The Lupus Landmark Study, the largest prospective observational study in lupus, will enroll 3,500 patients throughout North America over five...

Read More

Lupus Research Alliance and its Clinical Research Affiliate Lupus Therapeutics Launch the Lupus Landmark Study to Accelerate Personalized Treatments in Lupus

The Lupus Landmark Study, the largest prospective observational study in lupus, will enroll 3,500 patients throughout North America over five...

Investigational CAR T Cell Gets Fast Tracked by U.S. FDA

May 1, 2023 The LRA and our clinical arm Lupus Therapeutics are pleased to share good news from Cabaletta Bio,...

Read More

Lupus Research Alliance Unites the U.S. Food & Drug Administration (FDA) & Lupus Community to Launch Novel Public-Private Partnership

Lupus Accelerating Breakthroughs Consortium to address challenges impacting lupus trial success and to accelerate treatment breakthroughs  Washington, DC, March 29,...

Read More

Rinvoq Advances to Phase 3 in Lupus

March 27, 2023 Based on positive results of a Phase 2 clinical trial testing upadacitinib (Rinvoq®) given alone or with...

Read More

Lupus Research Alliance Appoints New Executive Vice President of Affiliate Lupus Therapeutics

NEW YORK, NY. January 17, 2023— The Lupus Research Alliance (LRA) is pleased to announce the appointment of Stacie J....

Read More

Promising Data Shows Lupus Research Alliance Peer Education Program Increases Intentions to Join Clinical Trials Among Diverse Patient Population

ACR Convergence 2022 Included LRA-Authored Research on Measures to Demonstrate Treatment Efficacy for Patients with Lupus NEW YORK, NY–November 8,...

Read More

Lupkynis® (voclosporin) Granted Marketing Authorization in the European Union for Lupus Nephritis

September 21, 2022 Lupkynis® (voclosporin) was just granted marketing authorization in the European Union as a new treatment for adults...

Read More

New England Journal of Medicine Publishes Positive Data of Litifilimab in Cutaneous Lupus Erythematosus

August, 2022 We are pleased to share positive results from the two-part Phase 2 LILAC study published in the New England...

Read More

Lupus Research Alliance and Lupus Therapeutics Response to Positive Data from Phase 2 Study on Potential First-in-class Lupus Treatment

June 1, 2022 The Lupus Research Alliance (LRA) and its clinical trial arm Lupus Therapeutics congratulate Bristol Myers Squibb (BMS)...

Lupus Research Alliance Applauds U.S. FDA Approval of AstraZeneca’s anifrolumab-fnia (Saphnelo™) for Systemic Lupus Erythematosus (SLE)

First in New Class of Drugs in More than a Decade for SLE Targeting Type 1 Interferons NEW YORK, NY....

Lupus Research Alliance Hails Approval of Aurinia’s Lupkynis(TM) (voclosoporin)

First Oral Treatment for Lupus Nephritis Second Lupus Treatment to Receive FDA Approval in Past Month NEW YORK, NY. January...

LRA Pleased to Share GSK’s Benlysta® (belimumab) is First Lupus Nephritis Treatment Approved by FDA

NEW YORK, NY. December 17, 2020. The Lupus Research Alliance (LRA) congratulates GSK on the U.S. Food and Drug Administration...

LRA Applauds GSK on Positive Phase 3 Study of Benlysta® in Lupus Nephritis

September 16, 2020 NEW YORK, NY. The Lupus Research Alliance welcomes positive BLISS-LN Phase 3 data published in this week’s New...

LRA Statement: Potential Lupus Nephritis Drug Voclosporin Granted Priority Review by the U.S. FDA

NEW YORK, NY. July 22, 2020. The Lupus Research Alliance congratulates Aurinia Pharmaceuticals Inc. on acceptance of its NDA filing...

Lupus Expert Dr. Richard Furie Addresses Clinical Trials

June 12, 2019 As reported by The Rheumatologist, Dr. Richard Furie provided his perspective on clinical trials in lupus in...

Positive Early Results for BIIB059 as New Treatment Strategy

March 1, 2019 Proteins of the immune system, known as type I interferons, are responsible in part for manifestations of...

People with Lupus at Higher Risk for Bone Fractures, Study Shows

February 22, 2019 A study published in the peer-reviewed journal Arthritis & Rheumatology found that people with SLE and particularly...

Physical Fitness Associated with Health-related Quality of Life, Study Shows

February 22, 2019 Study results published in the peer-reviewed journal PLOS One showed that elements of physical fitness — muscle...

Study Shows Kidney Transplant Improves Lupus Nephritis Survival

A study just published in Annals of Internal Medicine showed that kidney transplantation reduced deaths due to lupus nephritis— kidney inflammation caused by lupus....

Study shows: Stress, Depression and Pain are Major Contributors to Lupus Fatigue

An observational study published in Lupus of people with lupus found that of six factors,  stress, depression and pain contributed most to...

Existing Asthma Medication Shows Effectiveness for Lupus

A small randomized Phase 1 study published in Arthritis & Rheumatology found that the existing asthma treatment omalizumab (Xolair) may improve lupus...

New Trial Begins to Test Investigational Cenerimod to Treat Lupus

Source: Idorsia LTD Press Release Idorsia Ltd (SIX: IDIA)  announced that the first patient has been enrolled into a multiple-dose study...

Poor Dental Care Associated with Lupus

A study just published in Clinical and Experimental Rheumatologyfound that exposure to periodontal bacteria on the gums around the teeth can...

Association Between Lupus and Cancer

A new analysis published in Arthritis Research & Therapy found that SLE is associated with increased risk of 16 cancers and decreased...